drugset / Trial / NCT05850494

Study to Assess Bronchospasm Potentially Induced by Next-Generation Propellant vs HFA Propellant in an MDI in Participants With Well/Partially Controlled Asthma

NCT05850494 ↗

Phase 3 Completed 52 enrolled AstraZeneca
RandomizedCrossoverQuadruple-blindTreatment

Summary

A study to assess bronchospasm potentially induced by HFO MDI as compared with HFA MDI in participants with well controlled or partially controlled asthma

Timeline

Start
2023-05-02
Primary completion
2023-08-21
Completion
2023-08-21

Outcome

Met primary endpoint

paper noninferiority of HFO-1234ze pMDI versus HFA-134a was established for change from baseline in FEV1 AUC0-15 minutes post-dose between treatments PMID 40551410 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject HFO MDI Unknown 4 unknown Inhaled
Subject NORFLURANE Other / unclassified 4 unknown Inhaled

Indications